Jim Cramer advises investors to hold off on aggressively buying AI-related stocks despite a recent tech rebound, citing technical chart weaknesses and upcoming events as key hurdles. He highlights the need for improved stock charts, strong earnings reports from major tech firms, the outcome of the midterm elections, and a successful Anthropic IPO to restore confidence in the AI sector. Cramer remains bullish long-term but stresses these factors must align before the AI trade can sustainably recover.
Jim Cramer's caution on the AI rebound comes as Pluang's Technology sector shows mixed performance. For readers following tech stocks, here is Pluang's market snapshot as of Oct 20, 2026 05:21 WIB: out of 150 priced US tech stocks, 109 rose and 37 fell. Notable movers include AXTI at USD 57.32 with a +11.37% change and 58% buy orders, DOCN at USD 97.94 down -10.53% but with 100% buy orders, and APLD at USD 19.32 up +7.04% with a near even buy/sell split and a typical hold time of 25 days.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Nvidia announced a nearly $10 billion investment plan to support Europe's AI ecosystem, focusing on four German startups: Agile Robots, Avelios Medical, Mirelo, and Reflex Aerospace. This move aligns with Germany's goal to lead in industrial AI, with...
Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...
